Collegium Pharmaceutical, Inc. (Nasdaq GS: COLL) is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for patients suffering from chronic pain. Collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the Company’s proprietary DETERx® technology platform. Collegium’s lead product candidate, Xtampza ER™, is an abuse-deterrent, extended-release, oral formulation of oxycodone, and is the first of a number of product candidates using the DETERx technology. Xtampza ER has received Fast Track designation from the U.S. Food and Drug Administration (FDA).
Collegium had its initial public offering in May, 2015. It currently has a request before the FDA to convert its Tentative Approval for Xtampza ER to a Final Approval.